PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
According to a new study, among patients receiving extended anticoagulation with apixaban for cancer-associated VTE, four ...
In A-fib patients selected using established dose-reduction criteria, the 2.5-mg twice daily dose of apixaban (Eliquis; Bristol-Myers Squibb) provides protection against stroke and death versus ...
Apixaban is a generic prescription drug that’s used to treat or prevent certain blood clots. Apixaban’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...
Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...
The US Food and Drug Administration has approved two companies’ applications to make generic versions of apixaban, which will be the first generic versions of any direct oral anticoagulant (DOAC) ...
Discover comprehensive details about Apixaban, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban for the prevention of venous thromboembolism after elective total hip or knee replacement surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback